gliptins and renal disease
Last reviewed 01/2018
Gliptins and renal disease:
- gliptins, in general, predominately have renal excretion profile. The exception
is linagliptin which primarily excreted via bile and gut
- use in patients with chronic kidney disease (measured units are in terms
of creatinine clearance [CrCl])
- sitagliptin
- for patients with mild renal impairment (CrCl>= 50 ml/min), no dose adjustment is required
- for patients with moderate renal impairment (CrCl >=30 and CrCl<50 mL/min), the dose of sitagliptin is 50 mg once daily
- for patients with severe renal impairment (CrCl <30 mL/min) or with
end-stage renal disease (ESRD) requiring haemodialysis or peritoneal
dialysis, the dose of sitagliptin is 25 mg once daily
- saxagliptin
- no dose adjustment is recommended for patients with mild renal impairment
- dose of saxagliptin should be reduced to 2.5 mg once daily in patients with moderate or severe renal impairment
- experience in patients with severe renal impairment is very limited. Therefore, saxagliptin should be used with caution in this population
- not recommended for patients with end-stage renal disease (ESRD)
requiring haemodialysis
- vildagliptin
- no dose adjustment is required in patients with mild renal impairment (CrCl>50 ml/min)
- with moderate or severe renal impairment or with end-stage renal
disease (ESRD), the recommended dose of vildagliptin is 50 mg once
daily
- linagliptin
- no dose adjustment is required in patients with renal disease
- sitagliptin
For up to date details before prescribing a gliptin in renal impairment/disease then consult the relevant summary of product characteristics (SPCs)
Reference: